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From the
President

Research is to see what
everybody else has seen,
and to think what nobody else has thought.
- Albert Szent-Gyorgyi

•••••
Medicare Payments
As we read about the failure of Congress to avert the
scheduled 5.4% cut in 2002 Medicare physician
reimbursements, despite bipartisan support, one concludes
that physicians are being "used" to control Medicare spending.
Warren Jones, MD, president of the American Academy of FP,
confirmed that across the board 2002 payment cuts would
have "immediate negative consequences" on access to patient
care. He points out that physicians are facing rising practice
costs, soaring liability insurance premiums, and burdensome
regulatory loads.

We remain optimistic that Congress will act to reverse this illconsidered cut in Medicare payments.

•••••
I don't even like money; it just quiets my nerves.
-Bob Hope

•••••
Medical Manpower
December's Pro Tempore carried a report about the growing
shortage of physicians in southeastern Pennsylvania. The
newswire item below confirms that the issue is real. It is also
consistent with the numerous stories in the last year about the
"vanishing healthcare worker. • We are aware of the shortage
of nurses, pharmacists, skilled health aids, technologists,
physical therapists, radiology techs, etc. The "service
professions" are being stretched and stressed. We need to
understand the forces shaping our society while we value and
support each other as healthcare team members.
The U.S. will soon be facing a shortage of physicians that

will become progressively more severe, leading to a
deficit of 200,000 physicians by 2020, according to a study
in Health Affairs.
(Continued on Page 2)
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Using a newly developed physician supply trend model,
researchers said the data debunk predictions over the past 20
years that there would be a 15 to 30 percent surplus of
specialty physicians by 2000, reported AMNews. Researchers
said previous studies had failed to accurately account for
population growth, work-effort of physicians, contribution of
services by non-physicians and economic expansion, AMNews
added. (Health Affairs, January/February, 2002; American
Medical News, January 21, 2002)
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An alternative system that has worked in California for 26
years is a variation of workers' compensation no-fault system.
Countries in Scandinavia have a no-fault patient compensation
insurance system. Screening panels and arbitration are also
alternatives.

•••••

The medical staff enthusiastically supports medical
accountability and responsibility in patient safety efforts, which
require blame-free reporting of all medical errors and the
system changes to prevent such errors in the future. The
present tort system not only is NOT helping in this effort; it has
become an obstacle. In a way, the tort system is contributing
to continued patient injuries.

Bons mots
I'm living so far beyond my income that we may be said to be
living apart.
- E. E. Cummings

Nothing great was ever achieved without enthusiasm.
-Ralph Waldo Emerson (Circles)

•••••

Malpractice Crisis

Gov. Schweiker called on the State Legislature to put
"Strong Reforms" of PA's Medical Malpractice System at
the top of its agenda for January.
Schweiker gave no details, but he said the legislature should
address patient-safety issues as well as legal reforms,
reported the Philadelphia Inquirer.
LVHHN has continued to emphasize patient safety initiatives in
every aspect of patient care, and we understand that this is our
first priority. A comprehensive program (called Primum Non
Nocere) with multiple safety projects is underway with periodic
reports to Senior Management Council. Progress is being
made on a number of fronts.
Let us all think clearly about the essential elements of the
malpractice situation.
There are two separate questions here:
1. Do medical errors occur (yes) and are patients injured
as a result? (unfortunately, yes again).
2. What is the best system to reduce errors and protect
our patients?
Any impartial observer would conclude that the present tort
system has FAILED to reduce errors and compensate fairly
those patients injured by medical errors. (Less than one in
eight patients so injured is compensated.) In addition, the
COST has gotten out of control (about 60% of premium dollars
goes to our legal colleagues). As significant monetary
beneficiaries of the present tort system, the Pennsylvania Trial
Lawyers Association will find it impossible to be impartial in
these discussions. Our legislators should understand this. We
certainly do.

•••••

•••••
A swift first step in the struggle might be to reinstate the
malpractice legislation previously passed by the Legislature in
1997 and struck down by the PA Supreme Court...

Pennsylvania Attorney General Mike Fisher today sent a
letter to Chief Justice Stephen A. Zappala of the
Pennsylvania Supreme Court asking that the Court take
steps to alleviate the high costs of medical malpractice
insurance.
In January 1997, the Supreme Court suspended several key
provisions of the Health Care Services Malpractice Act, saying
it interfered with the court's rulemaking authority. The court
then ordered its Civil Procedural Rules Committee to
recommend changes to cover the
issues. However, no recommendations have been made. "... 1
would urge the court to consider reversing the suspension of
the provisions of Act 135." (Pennsylvania Office of Attorney
General, January 7, 2002)

•••••
A rich man is nothing but a poor man with money.
- W.C. Fields

•••••

Nursing at LVHHN - The Draw of the Magnet
At LVHHN, our nursing turnover rate has dropped from 16.5%
to 10%. Our vacancy rate is 7-10% - the lowest in years compared with national vacancy rates of 20%. We strive to
provide more individualized caring with ratios that exceed other
local hospitals and are excellent compared with national
averages.
(Continued on Page 3}
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At LVHHN, nurses have: a voice in decision making, active
role in nursing improvements, flexible schedules,
compensation incentives, scholarships, tiered float pool,
educational and professional development, succession
planning, endowed chair in nursing, three Nightingale of
Pennsylvania award finalists, and increased communications
with physicians.

•••••

Let us not look back in anger or forward on fear, but around in
awareness.
- James Thurber

•••••
PHO Update
With some recent contract signings by Mr. Greg Kile, Valley
Preferred (our wholly owned PPO) has become one of the
largest PPO's in Pennsylvania with 80,000 enrollment. The
PHO has enthusiastically supported the CAPOE project and
receives regular progress reports from Dr. Don Levick. The
hospital and the PHO (represented by Dr. John Jaffe) jointly
run the Care Management Council, which oversees LOS
issues among others. With the help of Dr. Paula Stillman and
medical staff members, successful efforts are underway to
reduce the LOS creep. We ask your help in this effort to
maximize our capacity and our ability to care for our
community.

•••••
Golfer:
Caddy:

"This golf is a funny game."
"It's not supposed to be."

•••••

Time may be a great healer, but it's also a lousy beautician.

Edward M. Mullin, Jr., MD
Medical Staff President

Attention: PalmPilot Users

The LVHHN Medical Staff Directory, a listing of
the LVHHN Residents, and the LVHHN
Telephone Hotlist are now available through the
Medical Staff Services Office. If you have a Palm
Ill, Palm V, Palm M505, or a HandSpring, the
above information can be hot synced to your
PalmPilot. For more information or to schedule a
convenient time to stop by, please contact Beth
Martin in Medical Staff Services at (610) 402-8980.
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Spotlight on ...
David P. Carney, MD
Dr. Carney is originally from State
College, Pa. He completed his
undergraduate education at the
Pennsylvania State University where he earned a Bachelor of
Science degree. He received his medical degree from
Hahnemann Medical College of Philadelphia. He completed a
rotating internship and medical residency at the Allentown
Affiliated Hospitals, and went on to serve as the first Chief
Medical Resident of that program.
Dr. Carney is certified in both Internal Medicine and Geriatric
Medicine by the American Board of Internal Medicine.
Dr. Carney joined the hospital's Medical Staff in 1979 and is a
member of the Department of Medicine, Division of General
Internal Medicine/Geriatrics. He is currently Associate Chief of
the Division of Geriatrics, and is the Medical Director of the
Lehigh Valley Transitional Skilled Unit at 17th &Chew. He is
also a Clinical Assistant Professor of Medicine at Pennsylvania
State University College of Medicine.
On a more personal note, Dr. Carney and his wife, Barbara,
have three children. In his spare time, Dr. Carney enjoys
sailing, music, and woodworking.
In conclusion, Dr. Carney has the following comments to share
with his colleagues on the Medical Staff:
"Medicine is a continuum, and we are responsible for
propagating our profession to those who follow. I'd like to
share some of the valuable lessons I've learned from those
who taught me."
"When the patient talks -listen. He is telling you his
diagnosis. • "Always try to treat people a little better than they
may deserve to be treated." - Paul L. Carney, MD
"Be attentive to detail in clinical examination, lest you miss
something important." - Stanley E. Zeeman, MD
"Within medical reason, give patients what they want- the
customer is always right." - Herbert L. Hyman, MD
• The core of professionalism is staying consistent and focused
in dealing with patients. • -Barre D. Kaufman, MD

"You're never alone in medicine when facing a problem; there's

a wealth of information waiting to help in the medica/library. •
-Dean F. Dimick, MD
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LVHHN to Expand Facilities and
Services at Lehigh Valley HospitalMuhlenberg
To better serve the needs of the growing and aging
Northampton County community, Lehigh Valley Hospital and
Health Network (LVHHN) has announced plans for the
continued expansion and improvement of facilities and
services at Lehigh Valley Hospital-Muhlenberg (LVHMuhlenberg) on Schoenersville Road in Bethlehem.
A multi-story building will be constructed to house an extension
of the network's Regional Heart Center and contain 56 beds for
critical care, cardiac and general medical/surgical patients.
Work on this pavilion is expected to begin in the fall and be
completed in June 2004. At its January 9 meeting, the health
network's board of trustees approved $39 million in funding for
these facilities and services improvements, of which $13.5
million ($8.5 million for invasive cardiology; $5 million for
surgery) is designated for Regional Heart Center expansion. A
comprehensive open heart surgery program, an integral part of
LVH's Regional Heart Center, will be launched at LVHMuhlenberg in June.
"This project further demonstrates LVHHN's continuing
commitment to providing high-quality and easily accessible
services at LVH-Muhlenberg to meet the health care needs of
our community in Northampton County and the surrounding
region," said Elliot J. Sussman, MD, LVHHN's president and
chief executive officer.
The Regional Heart Center space will comprise non-surgery
cardiology diagnostic testing and treatment services-two
cardiac catheterization/electrophysiology laboratories, and
patient preparation and recovery areas-and patient care units
for medical cardiology and recovering open heart surgery
patients.
In addition, the building will house an intensive care unit and a
general medical/surgical unit. The top floor will be reserved for
future development. The 100,000+-square-foot wing will be
located adjacent to the Children's Hospital of Philadelphia
Specialty Care Center on the western edge of the campus.
The new addition's entrance will face north, and it will be
visible and accessible from Routes 378 and 22 and
Schoenersville Road.
'
"The Lehigh Valley Health Network board of trustees has
studied this carefully for some time now, and we are excited to
invest further in the future health of the community as we bring
more services to Lehigh Valley Hospital-Muhlenberg," said
William Lehr, chairman of the board of LVH-Muhlenberg.
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Open heart surgery at LVH-Muhlenberg will be performed in a
specially designed operating room within the hospital's surgical
suite. During construction of the wing, a second cardiac
catheterization lab will be built on the hospital's second floor
adjacent to the current lab. This new lab will be moved to the
new building upon its completion, where a second new lab will
be added.
"These improvements will enhance and expand our ability to
provide high-quality heart care to any patient who comes to
this hospital," said cardiologist Anthony Urbano, MD, medical
director of interventional cardiology at LVH-Muhlenberg. "As a
Lehigh Valley Hospital and Health Network initiative, this
project brings to the LVH-Muhlenberg campus the combined
resources and expertise of a broad range of network
specialists."
Dr. Urbano and his colleagues in Lehigh Valley Cardiology
Associates -- the largest cardiology practice serving
Northampton County -- recently relocated their practice to a
larger facility on the LVH-Muhlenberg campus.
"Cardiovascular disease is the leading cause of death in the
U.S. and is primarily responsible for about 40 percent of all
deaths in the Lehigh Valley," said Fernando Garzia, MD, chief
of cardio-thoracic surgery at LVH-Muhlenberg. "With national
research predicting an even greater need for cardiology
services in the future, Lehigh Valley Hospital and Health
Network's decision to enhance heart services at the
Muhlenberg campus is an important step in responding to the
health care needs of Bethlehem and the surrounding
Northampton County communities. •
According to Robert J. Laskowski, MD, LVHHN's chief medical
officer, "We are expanding our 25-year-old nationally
recognized heart program at Cedar Crest &1-78 in response to
patients and physicians in Northampton County who desire

access to the resources of LVHHN's Regional Heart Center."
Work began in August to expand and modernize LVH's
Regional Heart Center located on its Cedar Crest & 1-78
campus in Allentown.
The LVHHN Regional Heart Center performs the largest
volume of interventional and surgical heart care in the region,
in keeping with its tradition of innovative leadership. The first
case of open heart surgery in the Lehigh Valley was performed
at Lehigh Valley Hospital, 17th &Chew (then called Allentown
Hospital) in 1974. The Regional Heart Center is also a pioneer
in new technologies, including the use of radiation to prevent
the ~-closing of vessels after angioplasty, and stenting;
beat1ng heart surgery; and radio-frequency ablation to cure
atrial fibrillation, an irregular quivering of the heart, which can
lead to stroke. Each year, cardiac care teams at LVHHN
(Continued on Page 5)
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perform 5,000 catheterizations, 1,900 angioplasties, 1,250
procedures for electrical problems of the heart, and more than
1,000 cases of open heart surgery.
Since the 1997 merger of LVHHN and Muhlenberg Hospital
Center, the following services and facilities have been added
at Lehigh Valley Hospital-Muhlenberg:
•!• The Children's Hospital of Philadelphia Specialty Care
Center
•!• The Behavioral Health Science Center
•!• The Lehigh Valley Hospital Cancer Center
•!• The region's only advanced technology in-vitro fertilization
laboratory
•!• The new ambulatory surgery unit, including the area's only
ambulatory pediatric surgery facility
•!• The Sleep Disorders Center
•!• The Wound Care Center
•!• The Rehabilitation, Physical Therapy and Sports Medicine
Center
•!• A new Breast Health Center

News from CAPOE Central
One of the advantages of a CAPOE system is the potential for
clinical decision support. The CAPOE system is an excellent
platform to provide physicians with feedback and information
pertaining to the orders being written. A great example of this
is the maximum dosing calculation, which has been created
through a tremendous amount of work by the Pharmacy
Department. When medications are ordered on-line, the
system will compare the order against the maximum dose
(both single dose and total daily dose) based on age. If the
maximum dose is exceeded, a warning will appear in the
Status Bar in the lower left comer of the screen. The alert is
for information only, and the ordering physician or provider can
still place the order.
A special"thank you" goes out to Karen Johnston, Mary Beth
Karoly and Janine Barnaby in the Pharmacy Department for
their hard work and energy in completing this project. Also,
many thanks to Jill Green and the rest of the Pharmacy
Department for their commitment and support The Pharmacy
identified the maximum dosing project as an important and
valuable clinical tool, and they worked hard to bring the project
to completion.
The success of CAPOE will come as a result of collaborative
work between all the departments and the desire by the
physicians and staff to improve patient care.
Don Levick, MD, MBA
(484) 884-4593 (office) or (610) 402-5100 7481 (pager)
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News from the HIM Department
Histories and Physicals
Over the past several months, two problems have been
identified relating to history and physical (H&P} documentation:
(1) H&P for elective admissions are done more than 30 days
prior to the scheduled admission; and (2) Transcription is being
requested to go back to old dictations and update with new
dates to meet the 30 day requirements.

Regulatory agencies require that histories and physicals be
dictated no more than 30 days prior to admission. History and
physical documentation not meeting regulatory requirements
will be returned to the physician.

Redictations
Are you looking for a report you dictated and can't find it in IDX
or PIM? Your first thought is that it must be lost in the dictation
system. The dictation system has proven to be very reliable in
ca~turing identifying information and dictations. Before you
redtctate the report, call the Transcription Department at (61 0)
402-8364 to verify whether or not the dictated report is in the
system. If you redictate the report, not only will this cause
duplicate dictations and work, but it will also have an effect on
the turnaround time of all dictations.
If you have any questions regarding these issues, please
contact Zelda Greene, Director, Health Information
Management, at (610) 402-8330.

Coding Tip of the Month

Non-specific Principal Diagnosis:
Identifies
principal diagnoses codes identified by the
Medicare Code Editor as Non-Specific diagnosis
for patients discharged alive that may indicate a
PRO review. More precise codes should be used
for the principal diagnosis.
CAN a more Specific code be assigned?
PLEASE, remember to specify: Sites, Chronicity,
and Organisms.
SITE: which specific topographical site of the
organ. Especially, important in malignancies and
other neoplasm.
Phlebitis -which vein was involved?
Mls -which site was the infarction?
CVAs - please specify cause such as embolus,
thrombus, or stenosis of cerebral artery with
infarct?

F

Information Services News
Customer Service
Information Services Customer Service (610-402-8303) is
covered 24 hours, seven days a week by the 1/S Helpdesk (the
first level of any 1/S assistance) and the 1/S Call Center (the
same department that handles the hospital Paging Services).
Normal Customer Service hours are Monday through Friday, 7
a.m. to 5:30p.m. During these hours, the department is
staffed to handle service calls directly to the Helpdesk, with
overflows going to the Call Center (to obtain the necessary
information to process calls and refer them to the Helpdesk
staff).
During off-shift hours, the Call Center will continue to answer
calls. Calls will be routed to the Computer Operator Staff for
assistance. If they can, they will handle the problem. If the
problem is out of the realm of the operator, and of a serious
nature, the call will be forwarded to the On Call team.
Unfortunately, the low volume of calls on the night shift does
not warrant around the clock Helpdesk service. In the event
that 1/S is unable to handle your call immediately, they will
make every effort to get back to you as soon as possible.

If you have any questions regarding this issue, please contact
Rob Bortz in 1/S Operations at (610) 402-1481.

Computer Passwords
Login passwords change every 90 days in compliance with
policy and regulatory requirements. When your password
expires, you will be forced to change it to a new password.
Your new password must:
1. Be at least six characters (a-zA-Z)
2. Contain at least one non-alphabet character (0-9,!@#...)
3. Contain at least one alphabet character
4. Be different from your user ID and your old password
How to Make It Easier
•!• Pick a word and add a sequence to it when it must
change:
Security1, Security2, Security3, ...
•!• Pick a word and substitute symbols for letters:
r011ca11 (a zero and some one's for the Ls)
r00tb33r (zero's and three's for the E's)
$talks (money talks)
•!• Use a song/poem/phrase to make a password:
Ride -across -the -river, -deep -and wide
-Ratrdaw
! Qledge ~llegiance !o !he ~ag
lpattf
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Changing Your Password

Normally when your password expires, you are prompted to
change your password during the login process. Follow the
instructions on the screen and the system 'walks' you through
the process.
You can also change your password at any time by initiating a
change. Press Ctri-Ait-Del and select the "Change Password"
option, then follow the instructions on screen.
If you have trouble with your account password, please call the
1/S Helpdesk at (61 0) 402-8303.

New Anti-Aging Medicine Initiative
In an effort to meet patient demands for enhancement of their
well-being and appearance, an Anti-Aging Medicine Program
has been established for Lehigh Valley Hospital and Health
Network. The Youthful You Institute at Lehigh Valley
Hospital-Muhlenberg will offer a comprehensive approach to
looking and feeling younger.
According to Robert X. Murphy, Jr., MD, who has been named
Medical Director for the Anti-Aging Medicine Program, "People
are excited about opportunities to improve their health and
appearance. Wellness, health and pampering are now a
combined experience. n
The Youthful You Institute at Lehigh Valley HospitalMuhlenberg, which will open its doors off the main lobby in
March, will offer the following services: natural nail care
services, skin care treatments, massage therapies,
nutrition/weight management therapies along with personal
exercise training consults, aesthetic procedures, physician
consultations, and physician-approved products. The phone
number for the Youthful You Institute is (484) 884-7045.
For more information regarding this new program, please
contact Greg Salem, Program Administrator, at (610) 4027000.

Currently, the secretary for the Diagnostic Care
Center at Cedar Crest & 1-78 answers the phone
number - (610) 402-8390 - for the Nuclear
Medicine Department.
Although she is not
physically located within the Nuclear Medi~ine
Department, she will direct calls to the appropnate
person.
All requests for reports/films should be directed to
the Radiology File Room at (61 0) 402-8070. This
includes requests for PET Scans.
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Community Acquired Pneumonia
Lehigh Valley Hospital participated in the national KePRO project-- Community Acquired Pneumonia (CAP). This project used five
quality indicators developed by the Health Care Financing Administration (HCFA) in consultation with content area experts. Data
obtained during the KePRO re-evaluation period (4/1/00 - 12/31 /00) revealed significant improvement in four out of five of these quality
indicators, as evidenced in the table below:

INDICATORS
Initial antibiotics within 8 hours after arrival
Initial antibiotics consistent with current recommendations
Blood cultures collected before antibiotics administered
Patient screened or given influenza vaccination (Oct-Dec)
Patient screened or given pneumococcal vaccination

Numerator
21
19
22
3
12

BASELINE
Denominator*
30
23
25
6
29

%
70%
83%
88%
50%
41%

REMEASUREMENT
Numerator Denominator*
40
44
39
42
35
37
11
18
16
46

%
91%
93%
95%
61%
35%

*The number of cases who qualified for the indicator. Th1s number differs for each indicator because of varying inclusion/exclusion
criteria.
However, LVH data from April, July, and October 2001 revealed three of these indicators, as well as Length of Stay (LOS) and Variable
Cost per Case improvements have not been sustained, as evidenced in the chart below:

1. Total # of Patients
2. Total LOS

3. Ave Var Cost/Case

DRG 89 PATIENTS WITH ADMITIING DIAGNOSIS OF PNEUMONIA
Target
Apr-01
13

Jul-01
20

Oct-01
23

Avg

5.0

4.7

5.3

7.0

#

$1,900

$1,632

$2,133

$3,529

2.4
6.1

2.9
4.3

10%
60%
70%

26%
74%
78%

4. Median Time
1.2
Hours
• Arrival until Antibiotic Ordered
3.0
Hours
3.0
• Arrival until Antibiotic Administration
5. Key Indicators
46%
80%
• Patients with Antibiotics started within 3 hours of arrival
92%
• Patients with Antibiotics started within 8 hours of arrival
100%
Patients
with
Blood
Cultures
drawn
before
Antibiotic
Administration
•
..
..
NOTE ·Admitting D1agnos1s of Pneumoma was detenmned by Phys1c1an documentation v1a chart rev1ew .

The current focus of the Community Acquired Pneumonia (CAP) team is to shorten time until antibiotics are ordered and administered.
Emergency Department and other physicians admitting patients with pneumonia are encouraged to help improve the quality of care to
pneumonia patients.
•

Please consider using the CAP pre-printed orders that are available in the Emergency Department and on all inpatient units.

•

KePRO Collaboration Newsletter (3/6/00) reports that the use of standing pre-printed orders has shown up to a 69%
improvement in some aspects of the quality of care.

•

Please remember to order the initial dose of antibiotic and blood cultures STAT in all pneumonia patients. Blood cultures should
be obtained prior to administration of antibiotics, if possible.

•

Consider administering the pneumococcal and/or influenza vaccine prior to hospital discharge in the clinically stable patients. The
CDC recommends the pneumococcal vaccine for patients over 65 and for those with chronic medical conditions. When unsure of
vaccination status, the CDC recommends administering one dose of vaccine.

•

If you have any questions, please contact Jay H. Kaufman, MD, LVH Physician Leader, KePRO Pneumonia Project, at Pager
(610) 920-7221 or Marlene Ritter, BS, RRT, at (610) 402-1707.
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Physician Assistance Program
Success in the work environment depends on everyone's
contribution. That's why no one can afford to ignore
depression.
According to the National Institute of Mental Health (NIMH),
America faces an epidemic of depression.
);;>
);;>
);;>

);;>

At any given time, one out of 20 workers suffers from this
disease
Every year, depression causes 200 million lost days of
work
Workplace depression drains $44 billion from the
economy each year, mostly because of absenteeism and
lower productivity
Depressed workers have between 1.5 and 3.2 more shortterm disability days

However, there is good news. More than 80% of depressed
people can be treated quickly and effectively. The key is to
recognize the symptoms of depression early and to receive
appropriate treatment. Unfortunately, nearly two out of three
people with depression do not receive the treatment they need.
The Medical Staff of Lehigh Valley Hospital recognizes that a
wide range of problems in life can affect a physician's health
and well being, and, at times, professional performance.
In fact, studies conducted by the National Institute for
Occupational Health and Safety report that physicians, along
with other caregivers, may have a higher than average risk of
developing debilitating personal problems.
Since 1993, the Physician Assistance Program has been
available to help members of the Medical Staff deal with
personal problems before they affect health, family life, or
professional effectiveness.
The Physician Assistance Program is a confidential (and if so
desired, anonymous), professional counseling and referral
service available to active members of the Medical Staff of
Lehigh Valley Hospital and their dependents.
This service is provided through an agreement with Preferred
EAP which operates the Lehigh Valley Hospital's Employee
Assistance Program (EAP) and has been involved with over
4,000 employees and dependents since 1985.
The Physician Assistance Program offers physicians and their
families counseling services for a wide range of personal
problems -- anything that can tum stress into distress including marital or relationship difficulties; depression and
anxiety; alcohol or drug abuse; family problems, or stress from
work or personal concerns.
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Program users can choose from a multi-disciplinary team
assembled to provide Physician Assistance Program services.
This team includes:
);;>
);;>

);;>

Michael W. Kaufmann, MD, Chairperson, Department of
Psychiatry
John C. Turoczi, EdD, licensed psychologist and member
of the Allied Health Professional Staff of Lehigh Valley
Hospital
Staff of Preferred EAP including licensed social workers,
masters level clinicians, and certified addiction counselors.

To use the Physician Assistance Program during normal
working hours, telephone the Preferred EAP office at (610)
433-8550 or 1-800-327-8878, identify yourself ONLY as a
member of the Lehigh Valley Hospital's Medical Staff (or a
family member), and ask to speak to the Clinical Manager,
Robin Chase, or Program Director, Oliver Neith. Please note
that callers may remain anonymous.
Ms. Chase, or the Preferred EAP receptionist, will conduct a
brief telephone interview, offer a choice among the above
listed provider team members, and advise the caller how to
arrange an appointment.
Other professional staff of Preferred EAP are available after
hours to respond to emergency situations.
The number of visits will vary with the nature and severity of
the problem. Up to five visits with Physician Assistance
Program providers are available to active Medical Staff
members (and their dependents) at no cost.
If their is a need for further service or treatment, a referral may
be made to a private practitioner or community resource, or the
user may continue with the original Physician Assistance
Program provider on a self-pay basis.
For more information, contact Robin Chase or Oliver Neith at
Preferred EAP at (610) 433-8550, or John W. Hart, Vice
President, in Medical Staff Services, at (610) 402-8980, or any
member of TROIKA.

? ? ? Mystery Medical Staff Member ? ? ?
? Born in Philadelphia
? Bachelor of Science degree at Wilkes College
? Medical degree from Hahnemann Medical College
of Philadelphia
? Three-year residency at Cleveland Clinic
Foundation
? One-year fellowships at both Brigham & Women's
Hospital and Hahnemann University Hospital
? Joined the Medical Staff in 1982
? Offices on LVH-M campus and on Pond Road
Give up? Please see Page 11 for the answer.
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· On-Call Policy for Nuclear Medicine
For your information, following is the on-call policy for the
Section of Nuclear Medicine at Lehigh Valley Hospital.
After hours and on weekends and holidays, a nuclear medicine
technologist and a nuclear medicine physician are on-call for
emergency cases only. These cases include ventilation
perfusion lung scans, Gl bleed scans, gallbladder scans to rule
out acute cholecystitis, nuclear medicine brain death scans,
and bone scans to rule out osteomyelitis in pediatric patients
who will be taken to the operating room that same day if the
scan is positive. In all non-emergent cases or if the scan
would not change the course of therapy for the patient that
day, the nuclear medicine study will be performed during the
next normal working day.

9

Pain Management Flow Sheet
As part of LVHHN's commitment to Pain Management and
compliance with JCAHO Standards, a new Pain Management
Flow Sheet has been instituted on all nursing units. The Pain
Management Flow Sheet will be utilized for ALL patients who
are receiving PCA or EPIDURAL analgesia, as well as patients
who receive ANY pain medication. The flow sheet will allow
you to better see your patients pain progress and response to
current pain management therapy.

As part of JCAHO regulations, the patient has a right to
ongoing assessment of pain, interventions to help meet
their pain goal and appropriate treatment of pain.
A copy of the Pain Management Flow Sheet is attached on
Page 14 for your information.

It is also important for the ordering physician to contact the
nuclear medicine physician on-call directly for any emergency
on-call case. This will provide the nuclear medicine physician
with important clinical information so that the technologist can
better tailor the study to that particular patient's needs if
indicated.

If you have any questions regarding this issue, please contact
Maryjane Cerrone, RN, Clinical Research Specialist,
Neurosciences and Pain Research, at (610) 402-9003.

It is felt that this policy will meet the emergency needs of our
patients and will optimally utilize hospital resources in terms of
radioisotope purchase and on-call technologists' time.

Mark A. Gittleman, MD, Division of General Surgery,
completed Auditor Training for the American College of
Surgeons Oncology Group (ACOSOG) and is now a certified
Auditor for clinical trials for the ACOSOG.

If you have any questions or concerns about the nuclear
medicine on-call policy, please contact Robert J. Rienzo, MD,
Chief, Section of Nuclear Medicine, at (610) 402-8373.

LOVARNews
The LOVAR (Lowering of Vascular Atherosclerotic Risk) Study
has recently completed recruitment of the 500 patients needed
for the intervention and control arms of the study. Although
recruitment of patients is now closed, the LOVAR team will be
following the 500 participants closely over the next three years.
The LOVAR team will continue to keep you informed of your
patient's progress in the study.
Using the principles and strategies gleaned in LOVAR, the
goal of the LOVAR team is to assist LVHHN and the medical
staff with building a program of vascular preventive medicine
and case management services for you and your patients.
Thank you for supporting the LOVAR Study for the past three
years.
If you have any questions or concerns regarding the LOVAR
Study, please contact John E. Castaldo, MD, LOVAR Principal
Investigator, or Jane Nester, MPH, MEd, LOVAR Co-Principal
Investigator, at (610) 402-4088.

Congratulations/

Peter A. Keblish, Jr., MD, Division of Orthopedic Surgery,
was awarded the 2001 Sir John Charnley Award. This award
was presented by the Arthritis Foundation at the Grand Soiree
--An Evening of Honors held October 20 at the Blue Mountain
Ski Area Special Events Center in Palmerton, Pa.
The Sir John Charnley Award is given for excellence and
achievement in the field of orthopedics. Sir John Charnley was
an English orthopedic surgeon who invented the modem total
hip replacement in 1962. He was a master surgeon, innovator
and bioengineer whose techniques have been studied by
surgeons around the world. Sir John Charnley's work has
contributed immensely to the relief of human suffering.

For Your Calendar
GLVIPA General Membership meetings have been
scheduled on the following dates:
•:• Tuesday, March 26, 2002
•:• Monday, June 24, 2002
•:• Tuesday, September 24, 2002
•:• Monday, December 16, 2002
All meetings will begin at 6 p.m., in the Auditorium of
Lehigh Valley Hospital, Cedar Crest & 1-78.

Medical Staff Progress Notes

February, 2002 •

Papers, Publications and Presentations
George A. Arangio, MD, Chief, Section of Foot and Ankle
Surgery, co-authored an article-- "Medial displacement
calcaneal osteotomy reduces the excess forces in the medial
longitudinal arch of the flat foot" - which was published in
Clinical Biomechanics 16 (2001) 535-539.
lndru T. Khubchandani, MD, Division of Colon and Rectal
Surgery, lectured at the Continuing Medical Education aspect
of the Association of Colon and Rectal Surgeons of India held
in Bombay on December 29-31, 2001. The symposium was
telecast at the Annual Meeting of the Association of Surgeons
of India in Patna, India.
Later in January, 2002, Dr. Khubchandani performed a surgical
procedure on one of the sheiks of the ruling family in Abu
Dhabi, United Arab Emirates.
Marisa A. Mastropietro, MD, Section of Pelvic Reconstructive
Surgery, recently had two peer reviewed articles published.
The first article- "Effect of Tension-Free Vaginal Tape
Procedure on Urodynamic Continence Indices" - was
published in Obstetrics & Gynecology, Volume 98, Number
4, October, 2001. The second -"Detrusor Biopsy as a
Potential Clinical Tool"-- was published in the International
Urogynecology Journal and Pelvic Floor Dysfunction,
Volume 12, Number6, 2001.
Alexander D. Rae-Grant, MD, Division of Neurology, authored
an article- "Transient Symptoms in MS"- which was
published in the Winter, 2001 edition of Multiple Sclerosis
Quarterly Report.
Craig J. Sobolewski, MD, Division of Primary Obstetrics and
Gynecology, and Residency Program Director, Department of
Obstetrics and Gynecology, attended the American
Association of Gynecologic Laparoscopists Global Congress of
Gynecologic Endoscopy held in San Francisco, Calif., in
November. "Laparoscopic Burch: Pearls Learned Over a
Seven Year Experience," a video which Dr. Sobolewski coproduced, was presented at the meeting.
Howard S. Selden, DDS, Division of Endodontics, authored a
paper- "Apexification: An Interesting Case" - which was
published in the January 2002 issue of the Journal of
Endodontics.
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Upcoming Seminars, Conferences and
Meetings
Emergency Medicine Grand Rounds
Emergency Medicine Grand Rounds are held on Thursdays,
beginning at 8 a.m., at alternate locations. Topics for February
will include:
February 7 • Banko Building, Rooms 1 & 2
•!• Pediatric Case Review- St. Luke's Emergency Medicine
Residency
•!• "The Quick Diagnostic Psychiatric Interview in the ED"
•!• "Management of the Difficult and Violent Patient"
•!• Ten Rashes You Must Know
February 14 ·4th Floor Conference Room· LVH·M
•!• M&M
•!• Resident Case Presentations
•!• Tintinalli (Pages 539-580)
February 21 • 4th Floor Conference Room • LVH·M
•!• Resident Case Presentations
•!• Alcohol Emergencies
February 28 • 4th Floor Conference Room • LVH·M
•!• Acute Coronary Syndrome Part II
•!• Abdominal Pain in the Elderly
•!• Satisfaction Guaranteed
•:• Tintinalli (Pages 580-669)
For more information, please contact Dawn Yenser in the
Department of Emergency Medicine at (484) 884-2888.

Medical Grand Rounds
Medical Grand Rounds are held every Tuesday beginning at
noon in the Auditorium of Lehigh Valley Hospital, Cedar Crest
&1-78, and via videoconference in the First Floor Conference
Room at LVH-Muhlenberg. Topics to be discussed in
February will include:
•!• February 5 - "Management of the Medically Complex
Geriatric Patient at Home"
•!• February 12- "Hematology for the Internist"
•!• February 19- "Life Ending Acts in the Dying Patient"
•!• February 26 - "DVD Prophylaxis in the Hospitalized
Patient - A Panel Discussion"

For more information, please contact Diane Biernacki in the
Department of Medicine at (610) 402-5200.
(Continued on Page 11)
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Department of Pediatrics
Pediatric conferences are held every Tuesday beginning at 8
a.m., in the Auditorium of Lehigh Valley Hospital, Cedar Crest
& 1-78. Topics to be discussed in February include:

•!• February 5 - "Medical Education: Techniques to Improve
Teaching"
•!• February 12- "Smiles for Tomorrow"
•!• February 19- "Imaging the Pediatric Abdomen"- Part 2
•!• February 26 - Case Presentation
For more information, please contact Kelli Ripperger in the
Department of Pediatrics at (610) 402-2540.

General Medical Staff Meeting
A General Medical Staff meeting will be held on Monday,
March 11, beginning at 6 p.m., in the Auditorium of Lehigh
Valley Hospital, Cedar Crest & 1-78, and via teleconference in
the First Floor Conference Room at Lehigh Valley HospitalMuhlenberg. During the meeting, "Malpractice Suit
Prevention" will be presented by Lawrence P. Levitt, MD,
Division of Neurology, and Janine Fiesta, Esq., Vice President,
Legal Services. All members of the Medical Staff are
encouraged to attend.
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Who's New
The Who's New section of Medical Staff Progress Notes
contains an update of new appointments, address changes,
resignations, etc. Please remember to update your directory
and rolodexes with this information.

Medical Staff
Appointments
Eugene B. Nor, MD
Christine &Bren Family Practice
1365 Blue Mountain Drive
Danielsville, PA 18038-9738

(610) 767-4315
Fax: (610) 767-9420
Department of Family Practice
Site of Privileges - None
Provisional Affiliate

Susan K. Pedott, DMD
(Solo Practice)
3894 Courtney Street, Suite 105
Bethlehem, PA 18017-8920
(610) 317-2400
Fax: (610) 317-8600
Department of Dentistry
Division of Endodontics
Site of Privileges - LVH & LVH-M
Provisional Active
Gary W. Szydlowski, MD
The Heart Care Group, PC
Jaindl Pavilion, Suite 500
1202 S. Cedar Crest Blvd.
P.O. Box 3880
Allentown, PA 18106-0880
(610) 770-2200
Fax: (610) 776-6645
Department of Surgery
Division of Cardia-Thoracic Surgery
Section of Cardiac Surgery
Site of Privileges - LVH & LVH-M
Provisional Active

Address Changes
Lehigh Valley Foot and Ankle Surgeons
•!• Jay H. Kaufman, DPM
•!• Dean L. Sorrento, DPM
1575 Pond Road, Suite 202

Allentown, PA 18104-2254
(Effective February 15, 2002)
(Continued on Page 12)
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Laurence P. Karper, MD
LVPG-Psychiatry
Lehigh Valley Hospital-Muhlenberg
2545 Schoenersville Road
5th Floor
Bethlehem, PA 18017-7384
(484} 884-6503
Fax: (484) 884-6504
Michael W. Kaufmann, MD
LVPG-Psychiatry
Lehigh Valley Hospital-Muhlenberg
2545 Schoenersville Road
5th Floor
Bethlehem, PA 18017-7384
(484} 884-6503
Fax: (484) 884-6504
Susan D. Wiley, MD
LVPG-Psychiatry
1255 S. Cedar Crest Blvd., Suite 3800
Allentown, PA 18103-6256
(610) 821-2036
Fax: (610} 821-2038

Practice Change.
Brendan J. O'Brien, DO
(No longer associated with Coordinated Health Systems}
Orthopaedic Associates of Allentown
1243 S. Cedar Crest Blvd.
Second Floor
Allentown, PA 18103-6268
(610) 433-6045
Fax: (610) 433-3605

Status Changes
Frank G. Baloh, MD
Department of Surgery
Division of Ophthalmology
From: Active
To: Affiliate
Site of Privileges - None
Thomas 0. Burkholder, MD
Department of Surgery
Division of Ophthalmology
From: Associate
To: Affiliate
Site of Privileges - None

Joseph J. Grassi, MD
Department of Medicine
Division of Physical Medicine-Rehabilitation
From: Provisional Active
To: Associate
Site of Privileges - LVH-M
Joseph Kavchok, Jr., MD
Department of Surgery
Division of Ophthalmology
From: Active
To: Affiliate
Site of Privileges - None
Dennis W. Kean, MD
Department of Pediatrics
Division of General Pediatrics
From: Active/LOA
To: Honorary
Robert Kiesel, MD
Department of Surgery
Division of Ophthalmology
From: Associate
To: Affiliate
S~e of Privileges - None
Howard J. Kushnick, MD
Department of Surgery
Division of Ophthalmology
From: Active
To: Affiliate
Site of Privileges - None
Alan B. Leahey, MD
Department of Surgery
Division of Ophthalmology
From: Active
To: Affiliate
Site of Privileges - None
Alan D. Listhaus, MD
Department of Surgery
Division of Ophthalmology
From: Active
To: Affiliate
Site of Privileges - None
Mamie P. O'Brien, DO
Department of Surgery
Division of Ophthalmology
From: Active
To: Affiliate
Site of Privileges - None
(Continued on Page 13)
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. (Continued from Page 12)

One-Year Leave of Absence
Steven L. Zelenkofske, DO
Department of Medicine
Division of Cardiology
From: Active
To: Active/LOA

Resignations
John R. Anderson, MD
Department of Surgery
Division of Urology
William F. Gadbois, MD
Department of Surgery
Division of Urology
Karen M. Matz, MD
Department of Obstetrics and Gynecology
Division of Primary Obstetrics and Gynecology
Peter J. Meyer, MD
Department of Psychiatry
Section of Child-Adolescent Psychiatry

Death
Raul M. Abad, MD
Department of Surgery
Division of Neurological Surgery

Allied Health Staff
Appointments
Guy T. Hornig, CRNA
Physician Extender
Professional - CRNA
(Lehigh Valley Anesthesia Services, Inc. - Thomas M.
McLoughlin, Jr., MD)
Site of Privileges - LVH &LVH-M
David J. lsgan, PA·C
Physician Extender
Physician Assistant - PA-C
(Gastroenterology Associates- Lawrence W. Barclawil, MD)
Site of Privileges - LVH &LVH-M
Craig I. Matsumoto, CNIM
Physician Extender
Technical
Intraoperative Neurophysiological Monitoring Specialist
(Surgical Monitoring Associates)
(Supervising Physician - Marl< C. Lester, MD)
Site of Privileges - LVH & LVH-M

Volume 1 Number 2
Heather L. Posavek, GRNA
Physician Extender
Professional - GRNA
(Lehigh Valley Anesthesia Services, Inc. - Thomas M.
McLoughlin, Jr., MD)
Site of Privileges - LVH &LVH-M
William R. Sevold
Physician Extender
Technical- Pacemaker/ICD Technician
(Guidant Corp)
(Supervising Physician - Norman H. Marcus, MD)
Site of Privileges - LVH & LVH-M
Mark E. Unger, CRNA
Physician Extender
Professional - CRNA
(Anesticare Anesthesia Services Inc)
(Supervising Physician -Thomas M. McLoughlin, Jr., MD)
Site of Privileges - Lehigh Magnetic Imaging Center only

Resignations
Donald G. Connell, CRNA
Physician Extender
Professional - CRNA
(Allentown Anesthesia Associates Inc)
John E. Kresge, CRNA
Physician Extender
Professional - CRNA
(Allentown Anesthesia Associates Inc)
Michael C. Loomis, CRNA
Physician Extender
Professional - CRNA
(Allentown Anesthesia Associates Inc)
Terrance McGinley, CRNA
Physician Extender
Professional - CRNA
(Allentown Anesthesia Associates Inc)
Ann J. Peiffer, PA-C
Physician Extender
Physician Assistant- PA-C
(Opcor, P.C.)
William J. Waldron, CRNA
Physician Extender
Professional - CRNA
(Allentown Anesthesia Associates Inc)
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THERAPEUTICS AT A GLANCE
The following actions were taken at the December 2001 Therapeutics Committee Meeting- Joseph Ottinger, R.Ph., MS, MBA, Janine Barnaby,
R.Ph., Jenny Boucher, Pharm.D., Viraj Patel, Pharm.D, Kimberly Pettis, R.D.

Formulary Additions
Nesiritide/Natrecor ™
N esiritide is indicated for the intravenous treatment of patients with acutely decompensated congestive heart failure
who have dyspnea at rest or with minimal activity.
Human b-type (brain) natriuretic peptide is an endogenous 32-amino acid peptide hormone found in brain and
cardiac tissue that exerts cardiovascular and renal activity. Although originally identified in porcine brain tissue,
it is now recognized to be excreted primarily by the cardiac ventricle. Nesiritide is synthetic human b-type
natriuretic peptide and is identical in amino acid sequence to the naturally occurring hormone. It is produced by
E. coli using recombinant DNA technology.
B-type natriuretic peptide is a vasodilator, reducing both preload and afterload, with additional diuretic and
natriuretic activity. B-type natriuretic peptide is structurally and functionally similar to atrial natriuretic peptide
(ANP). Levels ofboth endogenous peptides are increased in fluid overload states including congestive heart failure
and chronic renal failure. Normally, b-type natriuretic peptide levels are lower than those of atrial natriuretic
peptide; however, levels rise with cardiac injury in proportion to the severity of cardiac dysfunction and may exceed
atrial natriuretic peptide levels. In severe heart failure, levels ofb-type natriuretic peptide are greatly elevated (20
to 100-fold). It is believed that the two hormones play a complementary role in modulating cardiac function and
fluid status.
Nesiritide was associated with reduction in pulmonary wedge pressure, mean right atrial pressure, and systemic
vascular resistance, and increases in cardiac index and stroke volume index, with no effect on heart rate.
Following administration of the recommended nesiritide dosing regimen (2 meg/kg IV bolus followed by an
intravenous infusion dose ofO.Ol meg/kg/min), 60% of the 3-hour effect on pulmonary capillary wedge pressure
reduction is achieved within 15 minutes after the bolus. Within 1 hour, 95% of the 3-hour effect is achieved.
Approximately 70% of the 3-hour effect on systolic blood pressure reduction is achieved within 15 minutes. After
discontinuation or reduction of dose in patients with symptomatic hypotension, half of the recovery of the systolic
blood pressure toward baseline is observed in about 60 minutes. At higher doses, the duration of hypotension has
been prolonged to several hours· Pulmonary capillary wedge pressure returns to within 10% of baseline within 2
hours after discontinuation of nesiritide.
The effects of nesiritide persist longer than would be expected from the short half-life, possibly due to receptormediated hemodynamic effects.
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Natriuretic peptides are cleared from the circulation by three mechanisms: binding to natriuretic peptide clearance
receptors on endothelial cells resulting in cellular internalization and lysosomal proteolysis; proteolytic cleavage
by endopeptidases, such as neutral endopeptidases; and renal filtration.
Although nesiritide is partially eliminated through renal filtration, dosage adjustment is not required in patients with
renal insufficiency.
Nesiritide should not be used as primary therapy for patients with cardiogenic shock or in patients with a systolic
blood pressure less than 90 mmHg. Nesiritide use should also be avoided in patients suspected of having or known
to have low cardiac filling pressures.
It is not recommended for patients for whom vasodilating agents are not appropriate, such as patients with valvular
stenosis, restrictive or obstructive cardiomyopathy, constrictive pericarditis, pericardia! tamponade, or other
conditions in which cardiac output is dependent upon venous return.
At higher doses, hypotensive episodes occurred more frequently and were generally ofgreater intensity and duration
and more frequently required medical intervention. Administration of nesiritide is recommended only in settings
where blood pressure can be monitored closely. The nesiritide dose should be reduced or nesiritide therapy
discontinued if hypotension occurs. Nesiritide should be administered cautiously in patients with a systolic blood
pressure less than 100 mmHg at baseline. The potential for hypotension may also be increased when nesiritide is
administered with other medications that may cause hypotension, such as an ACE inhibitor.
Nesiritide may affect renal function. In patients with severe heart failure whose renal function may depend on the
activity of the renin-angiotensin-aldosterone system, treatment with nesiritide may be associated with azotemia.
At doses higher than 0.01 meg/kg/min, an increased rate of elevated serum creatinine over baseline compared with
other therapies was observed, although the rate of acute renal failure and need for dialysis was not increased.
The most common adverse effects have included hypotension and associated symptoms including headache, nausea,
substernal pain, diaphoresis, lightheadedness, and sinus bradycardia. Other adverse effects reported in clinical trials
have included palpitations, vomiting, superficial phlebitis, epigastric discomfort, and junctional rhythm.
Hypotension and nausea appear to occur more frequently at higher doses. Table 2 summarizes the adverse effects
occurring with at least 3% frequency during the first 24 hours of nesiritide infusion in several clinical trials.
In clinical trials, nesiritide has been administered concomitantly with diuretics, oral ACE inhibitors, digoxin, oral
vasodilators, dobutamine, anticoagulants, oral nitrates, statins, class III antiarrhythmic agents, beta-blockers,
calcium channel blockers, angiotensin II receptor antagonists, and dopamine.
The coadministration of nesiritide
with IV vasodilators such as nitroglycerin, nitroprusside, milrinone, or IV ACE inhibitors has not been evaluated
and these agents were not coadministered with nesiritide in clinical trials.
Nesiritide is administered intravenously. Blood pressure should be closely monitored during nesiritide
administration. If hypotension occurs during nesiritide administration, the dose should be reduced or discontinued
and other measures to support blood pressure should be started (IV fluids, changes in body position). In the VMAC
trial, nesiritide therapy was discontinued when symptomatic hypotension occurred and could be subsequently
restarted at a dose that was reduced by 30% (with no bolus administration) once the patient was stabilized.
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Hypotension may be prolonged up to hours; therefore, a period of observation may be necessary before restarting
nesiritide.
The recommended dose ofnesiritide is an IV bolus of2 meg/kg followed by a continuous infusion at a dose of0.01
meg/kg/min. Therapy should not be initiated at a higher dose. The infusion solution should be prepared by adding
1.5 mg to 250 ml of solution, resulting in a concentration of 6 mcg/mL of nesiritide. The IV tubing should be
primed with an infusion of25 mL prior to connecting the patient's vascular access port and prior to administering
the bolus or starting the infusion. To administer the bolus dose, the bolus volume recommended in Table 1 should
be withdrawn from the infusion bag and administered over approximately 60 seconds through an IV port in the
tubing. Immediately after administration of the bolus dose, an infusion should be initiated at a flow rate of 0.1
mL/kg/hr that will deliver a nesiritide infusion dose ofO.O 1 meg/kg/min. Table 1 or the following fonnulas should
be used to calculate the appropriate weight-based bolus volume and infusion flow rate:
Bolus volume (mL) = 0.33 x patient weight (kg)
Infusion flow rate (mL/hr) = 0.1 x patient weight (kg)
Table 1: Weight-Based Bolus Volume and Infusion Flow Rate:
Patient Weight
(kg)
60
70
80
90
100
110

Volume of Bolus
(mL)
20
23.3
26.7
30
' 33.3
36.7

Rate of Infusion
(mi.Jh)
6
7
8
9
10
11

In the VMAC trial, 23 patients who had central hemodynamic monitoring received increased doses of nesiritide.
The infusion dose was increased by 0.005 meg/kg/min no more frequently than every 3 hours up to a maximum dose
of 0.03 meg/kg/min. Nesiritide should not be titrated at frequent intervals. There is limited experience with
administration of nesiritide for longer than 48 hours.
Nesiritide is physically and/or chemically incompatible with injectable fonnulations ofheparin, insulin, ethacrynate
sodium, bumetamide, enalaprilat, hydralazine, and furosemide. Nesiritide should not be coadministered with these
agents through the same IV catheter. The preservative sodium metabisulfite is also incompatible with nesiritide
and injectable drugs containing sodium metabisulfite should not be administered in the same infusion line as
nesiritide. The catheter must be flushed between administration of nesiritide and incompatible agents. Nesiritide
binds heparin and could bind the heparin lining of a heparin-coated catheter, thereby reducing nesiritide delivery
to a patient. Nesiritide must not be administered through a central heparin-coated catheter.
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Table 2: Adverse Events Reported in the Product Labeling ofNesiritide:
1VMAC Trial I
Other Trials
Adverse Event
Nitrogly-cerin
(n=216)

Nesiritide
(n=273)

Control*
(n=256)

Nesiritide
0.015 meg/kg/min
(n=253)

Cardiovascular
Hypotension
12%
11%
8%
Symptomatic hypotension
5%
4%
3%
Asymptomatic hypotension
8%
8%
5%
Ventricular tachycardia (VT)
5%
3%
10%
Non-sustained VT
5%
3%
9%
Ventricular extrasystoles
1%
3%
6%
Angina pectoris
2%
2%
2%
<1%
<1%
Bradycardia
1%
Body as a Whole
20%
Headache
8%
9%
5%
1%
Abdominal pain
4%
Back pain
3%
4%
2%
Central Nervous System
4%
2%
3%
Insomnia
2%
3%
3%
Dizziness
Anxiety
3%
3%
1%
Digestive
Nausea
6%
4%
6%
2%
1%
1%
Vomiting
.
.
*includes dobutamme, mtlrinone, mtroglycerm, placebo, dopamme, mtroprusstde, or amrmone .

Nesiritide
0.03 meg/kg/min
(n=246)

22%
11%
12%
10%
9%
4%
6%
3%

35%
17%
20%
4%
4%
4%
2%
5%

9%
2%
2%

7%
3%
1%

6%
6%
3%

6%
5%
2%

9%
2%

13%
4%

CONCLUSION: Nesiritide may offer an alternative to dobutamine, nitroglycerin, nitroprusside, milrinone and
other agents used in the therapy of hospitalized patients with acute congestive heart failure. It may be less likely
to cause ventricular arrhythmias than dobutamine, but was associated with a high incidence of symptomatic
hypotension in earlier trials, which featured higher dosing regimens. The reduced dosage used in the VMAC study
and approved by the FDA resulted in a comparable incidence of hypotension V s. nitroglycerin. Nesiritide therapy
does help to lower the pulmonary capillary wedge pressure and improve other hemodynamic parameters in
hospitalized patients with decompensated heart failure, but its comparative advantages have not been clearly
illustrated in any trial to date. Additional comparative data are necessary to determine the role of nesiritide in the
therapy of acute congestive heart failure. A provisional formulary availability status was approved to allow for
cardiology to gain some experience with this agent in the treatment of acute decompensated congestive heart failure.
The Pharmacy will monitor patients receiving this agent and report back to theTherapeutics Committee its findings.
Twenty-four hours of therapy with nesiritide for an 80 kg patient (one vial) will cost $370, while comparable
therapy with milrinone would cost $360. Nitroglycerin infusion bottles currently cost the institution@ $1.10 per
100mg/250ml bottle. Three bottles would be required to treat an 80 kg patient at 200 meg/minutes for 24 hours.
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Dobutamine infusion dosed at 10 meg/kg min for this same patient would require 5 vials of 250mg for a 24 hour
treatment-costing $16.25. Nitroprusside infusion in this same scenario would cost $26.40.

Etomidate/Amidate
Etomidate is a hypnotic drug without analgesic activity. Intravenous injection of etomidate produces hypnosis
characterized by a rapid onset of action, usually within 1 minute. Duration of hypnosis is dose dependent but
relatively brief, usually 3-5 minutes when an average dose of 0.3 mglkg is employed. Immediate recovery from
anesthesia (as assessed by awakening time, time needed to follow simple commands and time to perform simple
tests after anesthesia as well as they were performed before anesthesia), based upon data derived from short
operative procedures where intravenous etomidate was used for both induction and maintenance of anesthesia, is
about as rapid as, or slightly faster than, immediate recovery after similar use of thiopental.
The most characteristic effect of intravenous etomidate on the respiratory system is a slight elevation in arterial
carbon dioxide tension (PaC02).
Reduced cortisol plasma levels have been reported with induction doses of0.3 mglkg etomidate. These persist for
approximately 6-8 hours and appear to be unresponsive to ACTH administration.
The intravenous administration of up to 0.6 mglkg of etomidate to patients with severe cardiovascular disease has
little or no effect on myocardial metabolism, cardiac output, peripheral circulation or pulmonary circulation. The
hemodynamic effects of etomidate have in most cases been qualitatively similar to those of thiopental sodium,
except that the heart rate tended to increase by a moderate amount following administration of thiopental under
conditions where there was little or no change in heart rate following administration of etomidate. There are
insufficient data concerning use of etomidate in patients with recent severe trauma or hypovolemia to predict
cardiovascular response under such circumstances.
Clinical experience and special studies to date suggest that standard doses of intravenous etomidate ordinarily
neither elevate plasma histamine nor cause signs of histamine release.
Etomidate is rapidly metabolized in the liver.
Etomidate is indicated by intravenous injection for the induction of general anesthesia. When considering use of
etomidate, the usefulness of its hemodynamic properties should be weighed against the high frequency of transient
skeletal muscle movements.
Intravenous etomidate is also indicated for the supplementation of subpotent anesthetic agents, such as nitrous oxide
in oxygen, during maintenance of anesthesia for short operative procedures such as dilation and curettage or cervical
conization.
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BECAUSE OF THE HAZARDS OF PROLONGED SUPPRESSION OF ENDOGENOUS CORTISOL AND
ALDOSTERONE PRODUCTION, THIS FORMULATION IS NOT INTENDED FOR ADMINISTRATION BY
PROLONGED
INFUSION.
Plasma Cortisol Levels Induction doses of etomidate have been associated with reduction in plasma cortisol and
aldosterone concentrations. These have not been associated with changes in vital signs or evidence of increased
mortality; however, where concern exists for patients undergoing severe stress, exogenous replacement should be
considered.
The most frequent adverse reactions associated with use of intravenous etomidate are transient venous pain on
injection and transient skeletal muscle movements, including myoclonus:
Transient venous pain was observed immediately following intravenous injection of etomidate in about 20% of the
patients, with considerable difference in the reported incidence (1.2-42%). This pain is usually described as mild
to moderate in severity but it is occasionally judged disturbing. The observation of venous pain is not associated
with a more than usual incidence of thrombosis or thrombophlebitis at the injection site. Pain also appears to be less
frequently noted when larger, more proximal ann veins are employed and it appears to be more frequently noted
when smaller, more distal, hand or wrist veins are employed.
Transient skeletal muscle movements were noted following use of intravenous etomidate in about 32% of the
patients, with considerable difference in the reported incidence (22. 7-63%). Most ofthese observations were judged
mild to moderate in severity but some were judged disturbing. The incidence of disturbing movements was less
when 0.1 mg of fentanyl was given immediately before induction. These movements have been classified as
myoclonic in the majority of cases (74%), but averting movements (7%), tonic movements (10%), and eye
movements (9%) have also been reported. No exact classification is available, but these movements may also be
placed into three groups by location:
Most movements are bilateral. The anns, legs, shoulders, neck, chest wall, trunk and all four extremities have been
described in some cases, with one or more of these muscle groups predominating in each individual case.
Results of electroencephalographic studies suggest that these muscle movements are a manifestation of
disinhibition of cortical activity; cortical electroencephalograms, taken during periods when these muscle
movements were observed, have failed to reveal seizure activity.
Other movements are described as either unilateral or having a predominance of activity of one side over the other.
These movements sometimes resemble a localized response to some stimuli, such as venous pain on injection, in
the lightly anesthetized patient (averting movements). Any muscle group or groups may be involved, but a
predominance of movement of the ann in which the intravenous infusion is started is frequently noted.
Still other movements probably represent a mixture of the first two types. Skeletal muscle movements appear to be
more frequent in patients who also manifest venous pain on injection.
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Other Adverse Observations include the following:

Respiratory System: Hyperventilation, hypoventilation, apnea of short duration (5-90 seconds with spontaneous
recovery), laryngospasm, hiccup and snoring suggestive of partial upper airway obstruction have been observed in
some patients. These conditions were managed by conventional countermeasures.
Circulatory System: Hypertension, hypotension, tachycardia, bradycardia and other arrhytlunias have occasionally
been observed during induction and maintenance of anesthesia. One case of severe hypotension and tachycardia,
judged to be anaphylactoid in character, has been reported.
Gastrointestinal System: Postoperative nausea and/or vomiting following induction of anesthesia with etomidate
is probably no more frequent than the general incidence. When etomidate was used for both induction and
maintenance of anesthesia in short procedures such as dilation and curettage, or when insufficient analgesia was
provided, the incidence of postoperative nausea and/or vomiting was higher than that noted in control patients who
received thiopental.
Etomidate injection is intended for administration only by the intravenous method. The dose for induction of
anesthesia in adult patients and in children above the age of 10 years will vary between 0.2 and 0.6 mg/kg ofbody
weight, and it must be individualized in each case. The usual dose for induction in these patients 0.3 mg/kg, injected
over a period of 30-60 seconds. There are inadequate data to make dosage recommendations for induction of
anesthesia in patients below the age of 10 years; therefore, such use is not recommended.
Smaller increments of intravenous etomidate may be administered to adult patients during short operative
procedures to supplement subpotent anesthetic agents, such as nitrous oxide. The dosage employed under these
circumstances, although usually smaller than the original induction dose, must be individualized. There are
insufficient data to support this use of etomidate for longer adult procedures or for any procedures in children;
therefore, such use is not recommended. The use of intravenous fentanyl and other neuroactive drugs employed
during the conduct of anesthesia may alter the etomidate dosage requirements.
Conclusion: Etomidate has been utilized for almost 20 years. It is considered a safe and effective induction agent
The current cost for etomidate 40mg/20ml is $13.90. An induction dose of 0.2mg/kg of etomidate will cost about
$7.00. An equivalent dose of thiopental would cost $3.50. Its selected use in anesthesia and the ER areas is
anticipated.

Valganciclovir Hydrochloride/ Valcyte ™
V alganciclovir has been recommended for approval for use in the induction and maintenance treatment of
cytomegalovirus retinitis in patients with AIDS. Table 1 compares the other agents approved for this indication.
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Table 1: Antiviral Agents Used in the Treatment ofCMV Retinitis:
Generic Name

Brand Name
Manufacturer

Cidofovir
Cidofovir
Cidofovir
Vis tide
Gilead

Fomivirsen

Foscarnet

Ganciclovir
Insert

Ganciclovir
IV

Ganciclovir
PO

Valganciclovir

Vitravene
Ciba Vision

Foscavir
AstraZeneca

Vitrasert
Bausch &
Lomb

Cytovene-IV
Roche

Cytovene
Roche

Va/cyte
Roche

X

X

Indications
CMV retinitis in
immunocompromised
patients, including
patients with AIDS
CMV retinitis in
patients with AIDS
CMV retinitis in
patients with AIDS
who are intolerant of or
have a contraindication
to other treatments for
CMV retinitis or who
were insufficiently
responsive to previous
treatments
Induction
Maintenance
Combination therapy in
CMV retinitis
Prevention of CMV
disease in organ
transplant recipients
Prevention of CMV
disease in patients with
advanced HIV infection
Acyclovir-resistant
mucocutaneous HSV
infection in
immunocompromised
patients
..
a~ant1c1pated upon approval

X

X
X

X

xxxx
X

X
X

xa

X

X
X

X
X

X

X

X

xa
xa

X

X

Valganciclovir is rapidly and completely hydrolyzed to ganciclovir following oral administration. The absolute
bioavailability of ganciclovir from valganciclovir is approximately 60%. In contrast, the bioavailability of oral
ganciclovir is about 6%. Unlike ganciclovir, valganciclovir is a substrate ofthe intestinal peptide transporter PEPTI,
resulting in its increased bioavailability. Hepatic and intestinal esterases rapidly convert valganciclovir to
ganciclovir.
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Phase III studies are ongoing with valganciclovir for the prevention of CMV retinitis in solid organ transplant
recipients. The manufacturer is currently conducting a double-blind, multicenter study comparing valganciclovir
900 mg once daily and oral ganciclovir 1000 mg three times daily for the prevention of CMV disease in high-risk
heart, liver, and kidney allograft recipients.
The contraindications, warnings, and precautions for valganciclovir are similar to those of ganciclovir..
The most frequently observed adverse events during valganciclovir induction therapy included diarrhea, nausea,
vomiting, fever, fatigue, headache, oral candidiasis, neutropenia, anemia, and thrombocytopenia
Diarrhea occurred more frequently with valganciclovir than IV ganciclovir (16% vs 10%); however, nausea occurred
more frequently with IV ganciclovir (14% vs 8%). During valganciclovir maintenance therapy, 29% of patients
treated with valganciclovir induction therapy developed hemoglobin levels below 8 g/d.L compared to 16% of
patients who had received IV ganciclovir.
As valganciclovir is rapidly converted to ganciclovir, the drug interactions associated with ganciclovir will also
apply to valganciclovir. Seizures have been reported in patients who received ganciclovir and imipenem-cilastatin;
therefore, concomitant use is not recommended unless the potential benefits outweigh the risks.
Drugs that inhibit replication of rapidly dividing cell populations such as bone marrow, spermatogonia, and
germinal layers of skin and gastrointestinal mucosal may have additive toxicity when administered with ganciclovir.
Such agents would include dapsone, pentamidine, flucytosine, vincristine, vinblastine, doxorubicin, amphotericin
B, co-trimoxazole, or other nucleoside analogs.
Recommended monitoring should be similar to that for ganciclovir and includes frequent complete blood counts
and platelet counts, especially in patients with a history of leukopenia during ganciclovir therapy or in whom
neutrophils counts are less than 1000 cells/mL upon initiation of therapy. Serum creatinine or creatinine clearance
should also be closely monitored to allow for dosage adjustments in patients with renal impairment.
The dose evaluated in the primary clinical trial in patients with AIDS and CMV retinitis used an oral valganciclovir
dose of 900 mg twice daily for 21 days during induction therapy followed by 900 mg once daily for maintenance
therapy.
CONCLUSION: Valganciclovir appears to offer a promising alternative to oral and intravenous ganciclovir, with
the advantage of once- or twice-daily oral administration. It appears to achieve ganciclovir levels comparable to
those achieved with the intravenous administration of ganciclovir, and appeared as effective as intravenous
ganciclovir in the induction therapy of CMV retinitis in patients with AIDS. Although the efficacy of the
valganciclovir in maintenance therapy has not been established in clinical trials, there is no reason to believe it
should not be as effective as oral or intravenous ganciclovir in maintenance therapy based on the levels of
ganciclovir achieved in pharmacokinetic studies. The adverse effects ofvalganciclovir appear comparable to those
of ganciclovir. Currently, 1 gram of oral ganciclovir administered thrice daily would cost $75.00/day, while
900mg/daily ofvalganciclovir costs $46.75.
The improved bioavailability of this agent makes it especially attractive in the regimens of renal transplant
patients.
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Angiotensin Receptor (ARBs) Formulary Streamlined
No study has shown any of these agents to be preferable over the angiotensin converting enzyme inhibitors (ACEI)
in controlling blood pressure, improving the clinical status of patients with heart failure (sans ELITE 1) or in use
in mitigating the effects of diabetic nephropathy. Although, in patients that can not tolerate ACEI therapy,
angiotensin receptor blockers may provide an alternative in these situations. Certainly, no published comparative
study has suggested that any of the individual molecules has any superiority vs. other members of this drug class
in these two latter areas.
Based on the limited comparative studies in hypertension, irbesartan was at least as effective as either losartan or
valsartan. Candesartan was considered equivalent to losartan at low doses and statistically superior to losartan in
higher doses in one study. Irbesartan and candesartan have the most bioavailability amongst all the currently
available agents and can be dosed on a once daily basis. Both products have no demonstrated food/drug
interactions. Candesartan does require biotransformation, but this is not a clinically relevant limitation. Neither
agent requires dosing modifications in renal dysfunction. As candesartan will provide some marginal cost savings
and it allows for a stratified dose adjustment across multi-product dosage ranges, it was selected as the primary
angiotensin receptor blocking (ARB) agent for the LVH Formulary. Losartan will also remain on the Formulary
for its unique uricosuric effects and its current high frequency of use amongst this class of drugs.
Candesartan will be substituted for the other current ARBs based on the dosing schedule elucidated below. Patients
on losartan therapy WILL NOT have their therapy modified.
Approved Dose conversions (based on total daily doses)
Candesartan
lrbesartan
Valsartan
4mg
75mg
80mg
8mg
150mg
160mg
16mg
225mg
240mg
32mg
300mg
320mg

Candesartan

Telmisartan

Eprosartan

8mg

40mg

600mg

8mg

40mg

600mg

16mg

80mg

400mg bid

16mg

80mg

400mg bid

Comparative Acquisition Costs for ARBs based on Total Daily Dosage
Losartan
2Smg=$1.02
SOmg=$1.02
7Smg=$2.04
100mg=$1.46

Valsartan
SOmg=$1.04
160mr-$1.13
240mg=S2.17
320mg=$2.16

Candesartan
4mg=$1.10
Smr-$1.10
16mg=$1.10
32mg=S1.47

Telmisartan
40mg=S1.11

Eprosartan
600mg=$1.07

SOmg=$1.18

800m_rl1.60

lrbesartan
7Smg=$1.11
150mg=$1.17
22Smg=S2.18
300mg=S1.33
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Comparative Pharmacology
Parameter
Losartan
Food
10%
Interactions
decrease
Drug
RifamJ!in,
Interactions
fluconazole

Valsartan
SO%
decrease
None

Irbesartan
None

Candesartan
None

None

None

Telmistartan
20%
decrease
Digoxin

Eorosartan
Delaied
absorotion
None

0demethiiatio
!!.

Minimal
metabolism

Glucuronide
conjugation

4 lmeta 3-1n
Unknown
Change in

24
No Change

S-9
No Change

Unknown
Chang:e in

No Chang:e

Metabolism

2C9and 3A4

Unknown

T Yz {hr}
HeJ!atic
disfunction

2 (meta 6-9)
Decrease
initial dose

6
Unknown
Change in

Glucuronide
oxidation
and
conjugation,
2C9
11-15
Unknown
Change in

~

~

~

disease
Unknown
Chang:e in

disease
No Change

disease
No Change

Renal
disfunction
(If NOT
volume
depleted)
Active
metabolite

No Change

Yes

~

~

disease

disease

No

No

Yes

No

No

Additional Proton Pump Inhibitor Autosubstitutions
The Therapeutics committee approved therapeutic substitutions for two additional agents in the proton pump
inhibitor category. The Phannacy was authorized to change rabeprazole (Aciphex) and esomeprazole (Nexium)
to pantoprazole (Protonix). The updated class conversions are as follows:
Rabeprazole

Pantoprazole

20mgQD
40mgQD

40mgQD
40mgBID

Esomeprazole

Pantoprazole

20-40mgQD
40mgBID

40mgQD
40mgBID

Lansoprazole

Pantoprazole

15 mg QD or BID
30mgQD
30mgBID

40mgQD
40mgQD
40mgBID

Omeprazole

Pantoprazole

10-20mgQD
20mgBID
40mgQD
40mgBID

40mgQD
40mgQD
40mgQD
40mgBID

SPECIAL ISSSUE- do not use these dangerous abbreviations or dose designations ·
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Abbreviation/Dose
Expression

!Intended Meaning

"Misinterpretation

!!correction

'Apothecary symbols

ll:~n~m

I Misunderstood or misread (symbol for dram misread for "3" and
minim misread as "mL").

IUse the metric system.

!Au

llaurio uterque (each ear)

IDIC

I discharge
. d1scontmue

IIMistaken for OU (oculo uterque-each eye).
lloon't use this abbreviation.
Premature discontinuation of medications when D/C (intended to
Use "discharge" and
mean "discharge") has been misinterpreted as "discontinued"
"discontinue."
when followed by a list of drugs.

IAZT

II
llvidarabine

I

zidovudine
(RETROVIR)

ICPZ

IICOMPAZINE
.. (prochlorperazme)

IDPT

IDEMEROLPHENERGANTHORAZINE

jHCl

llhydrochloric acid

I
llcytarabineARA•c

I
I

Use the complete spelling for
drug names.

!Drug names
IARNA

I

I

Iazathioprine

IIchlorpromazine
ldiphtberi,_portu,.,i•-t-"' (v"dne)

II

I

I

I

I

llpotassium chloride (The "H" is misinterpreted as "K.")

jHCT

!!hydrocortisone

ijhydrochlorothiazide

!HCTZ

jjhydrochlorothiazide

llhydrocortisone (seen as HCT250 mg)

IMgS04

llmagnesium sulfate

llmorphine sulfate

jMS04

llmorphine sulfate

llmagnesium sulfate

IMTX

llmethotrexate

llmitoxantrone

I

ITAC
jznS04

lltriamcinolone

lltetracaine, ADRENALIN,cocaine

jjzinc sulfate

llmorphine sulfate

!stemmed names

I

J
J

!"Nitro" drip

jjnitroglycerin infusion

IIsodium nitroprusside infusion

I"Norflox"

llnorfloxacin

IINORFLEX

Ill g

I
I

lirnicrogram

!!Mistaken for "mg" when handwritten.

,o.d. orOD

llonce daily

I

I!Use ''meg."

lnwortiw

llthree times a week.

I!Mistaken as "three times a day."

llnon't use this abbreviation.

!per os

IIorally

liThe "os" can be mistaken for "left eye."

,q.d. orQD

llevery day

I Mistaken as q.i.d., especially if the period after the "q" or the tail
of the "q" is misunderstood as an "i."

lqn
jqhs

llnightly or at bedtime

I!Misinterpreted as "qh" (every hour).

lluse "nightly."

!!nightly at bedtime

IIMisread as every hour.

lluse "nightly."
lluse 6 PM "nightly."

lq6PM, etc.

II every evening at 6 PM

,q.o.d. or QOD

llevery other day

II

Misinterpreted as "right eye" (OD-oculus dexter)and
administration of oral medications in the eye.

IIMisread as every six hours.

I

Misinterpreted as "q.d." (daily) or "q.i.d. (four times daily) if the
"o" is poorly written.

IUse "daily."

I

IUse "every other day."
Use "subcut." or write
"subcutaneous."

l'ubq

ll'uboumneo"'

jsc

IIsubcutaneous

"Mistaken for SL (sublingual).

IU oru

llunit

I

lw
Icc

llintemational unit

I!Misread as IV (intravenous).

lluse "units."

llcubic centimeters

IIMisread as "U" (units).

lluse "mL."

lx3d

l!for three days

IIMistaken for "three doses."

lluse "for three days."

IBT

llbedtime

IIMistaken as "BID" (twice daily).

lluse "hs."

II

II

II

I
I

Use "PO," "by mouth," or
"orally."
Use "daily" or "every day."

I The "q" has been mistaken for "every" (e.g., one heparin dose
ordered "sub q 2 hours before surgery" misunderstood as every 2
hours before surgery).

Read as a zero (0) or a four (4), causing a 10-fold overdose or
greater (4U seen as "40" or 4u seen as 44").

I

I

I
I

I

I

Use "subcut." or write
"subcutaneous."

jj;'Unit" has no acceptable
abbreviation. Use "unit."

I
I
I
I

SPECIAL ISSSUE - do not use these dangerous abbreviations or dose designations ·
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I~·================~·~(a=po=t=h=ec=my==)========~~·~======~======~======================~ll~·=·o=n=e-=h=ru=f='o=r=u=se=="Y,=2·="====~II
ss

sliding scale (insulin) or 'h 'Mistaken for "55."

~~'>==;m=d=<==========l' greater than and less than
/ (slash mark)

I separates two doses or
indicates "per"

'Mistakenly used opposite of intended.
Misunderstood as the number I ("25 unit/10 units" read as "110"
units.

1

1:=======~

Name letters and dose
numbers run together

llnderal 40 mg

IIMisread as lnderal 140 mg.

llspell out "sliding scale." Use

I~:::reater

than" or "less

Do not use a slash mark to
separate doses.
Use"per."
I Always use space between
drug name, dose and unit of

~(e=.g~··=m=d=e=ra=l4=0=m=g=)====~~================~?======================================~?m=e=as=u=re=·============~
Zero after decimal point
(1.0)

II mg

I Misread as 10 mg if the decimal point is not seen.

No zero before decimal
dose
(.5 mg)

0.5 mg

IIMisread as 5 mg.

Do not use terminal zeros for
doses expressed in whole
numbers.

I Always use zero before a
decmtal when the dose ts less
thana

1

whole unit.
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MEC Approval for Expanded Role ofRegistered Dietitians
The following recommendations by the Therapeutics Committee for the Expanded Role of Registered
Dietitians have been approved by the MEC.

I. Registered Dietitians Taking Verbal Orders- MEC approval 9/4/01
Registered Dietitians may take verbal orders from physicians related to nutritional care and to
document those orders in the patient record.
Changes to the Rules and Regulations to conform to the recommendation are:
C. Patient Care #2
(a) Verbal Orders:
(iv) Verbal orders shall be taken only by a professional nurse except that the following
individuals may take verbal orders: .......... Registered Dietitians............. each
with respect to procedures they are authorized to perform.
(b) Telephone Orders:
(iii) Telephone orders shall be taken only by a professional nurse except that the following may
take telephone orders: ...........Registered Dietitians ............ with respect to procedures they
are authorized to perform.
II. Expanded Role of Registered Dietitians- MEC approvall2/4/0l
1. May provide discharge diet education to patients different from current order
(Example: post-op patient currently on Clear Liquids being given discharge diet education
for low residue diet for when he goes home)
2. May adjust diet orders, based on RD assessment, without obtaining physicians's order
(Example: current diet order for Regular diet, but patient doesn't have dentures; RD adjust
to mechanical soft diet)
3. Certified Nutrition Support Registered Dietitian may adjust tube feeding rates and products
(Therapeutic Substitution) without physicians orders.
Therapeutic Substitution is an approved practice throughout the organization. It is well documented that
timely nutrition intervention is crucial to positive patient outcomes and reduced length of stay. The
American Society for Parenteral and Enteral Nutrition Standards of Practice for Nutrition Support
Dietitians states: "[Nutrition Support Dietitians] may recommend, write orders, or obtain verbal orders
for enteral and parenteral formulations (as guided by professional licensure or delineated by clinical
privileges of an institution)". The Joint Commission on Accreditation of Health care Organizations
Standards, standard TX.4.2 states, "Food and nutrition products are administered only on the
prescription or order of a medical staff member or another individual who has been granted clinical
privileges to write such prescriptions or orders." Therefore, clinical privileges as stated above is
permissible.
The clinical privileges outlined above will enable the provision of timely Medical Nutrition Therapy
(MNT) significantly reducing the drain on Dietitian, Nursing, and Physician time in receiving orders to
initiate routine nutrition care plans. This time will better be spent on direct patient care and more
effective communication discussing a patients's medical condition, treatment plan, and progress with the
patient care team. The entire clinical nutrition team at LVHN is dedicated in providing the highest
quality MNT in support of our physicians and patients. We appreciate your continued support.
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The Last Word ...
Tips and Techniques for the LastwordTM User

February, 2002- Volume I, Issue 4

CAPOE: What's it all About?
by Carolyn K. Suess, R.N.
Over the past year the term CAPO£ has
been heard throughout the corridors of
Lehigh Valley Hospital. Computer
Assisted Physician Order Entry has
certainly created a lot of excitement, as
well as some confusion as to
expectations of physicians. To help
alleviate any feelings of uncertainty, it is
important to communicate expectations
to those that will receive CAPOE
training in the near future, and at the
same time dispel some myths.

Myth #1 : I have to be a computer
expert to master CAPOE
Anyone newly introduced to CAPOE is
not expected to be a computer expert.
The system is intuitive by design and
typing is kept to a minimum. The
greatest challenge is time. The CAPO£
Order Pad arranges orders in a logical
fashion by ordering department, and the
more time spent using CAPOE the easier
it becomes to find orders in the system.
Additionally, multiple orders that are
commonly placed at the same time (such
as admission orders) are grouped into
CAPOE Order Sets. Order sets alleviate
the need to search for orders individually
in the system.
You will be notified through your
chairman when you are expected to
begin using CAPOE. An appointment
for training with a Physician Software

Educator will be arranged through your
office manager.
One-on-one training is conducted
privately, to avoid distractions, and is
"hands-on." A minimum of two hours of
training time is required to learn the
CAPOE system. However, if additional
time is needed, the physician will be
accommodated. Reference material, in
the form of a user guide is provided to
every physician trained in CAPOE.

Myth #2: Once I'm trained, I'm on
my own
No one is ever left without a resource to
fall back on. Problems and questions
pertaining to CAPOE are addressed
through the Helpdesk extension 8303,
option #9. You will be prompted to
enter your call back phone number, and
the on-call trainer/analyst will return
your call immediately.
After a CAPOE unit activation, on-site
user assistance is provided for the first
few weeks by Physician Software
Educators and I.S. Analysts. Following
this period, Physician Software
Educators round on a regular basis to
provide additional assistance while
physicians are on the unit.
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Myth #3: If I don't have time to
enter my orders, I can just give
the nurse a verbal order

not available or if they are not working
properly, please contact the Helpdesk for
assistance, or page a Physician Software
Educator directly.

Although this may sound reasonable, the
expectation is for physicians to enter
their own orders once they have been
trained on CAPOE. Of course, there may
be extenuating circumstances. If you are
experiencing difficulty finding or
placing an order, it is important to
contact the Helpdesk immediately (ext.
8303, option #9).

Myth #6: I have to be on the
patient's unit to enter my orders
This is not true. CAPOE orders can be
entered from any Lastword workstation
and may also be entered remotely, from
the physician's office. This is
particularly convenient when admitting a
patient to the hospital directly from the
physician office.

Myth #4: I won't need to look up
patient labs and vital signs on-line
because the nurse will print them
and place them on the chart

As we know, change is inevitable and
CAPOE is bringing significant positive
changes to Lehigh Valley Hospital. The
Physician Software Educators on staff
are here to smooth the transition to
computer order entry, and you are
encouraged to contact them with any
training issues you may have:

For units that have implemented
electronic entry of vital signs and
medication administration as a prelude
to CAPOE, the expectation is for
physicians (both CAPOE and nonCAPOE) to view them on-line. Nursing
staff will not print reports and place
them on the chart, since more accurate
and timely information is available in the
Lastword system.

Lynn Corcoran-Stamm- ext. 1425
Kimberlee Szep, R.N.- ext. 1431
Carolyn K. Suess, R.N.- ext. 1416
If you have training needs that pertain
only to the Lastword system, please call
ext. 1703. Arrangements can be made
for training at your convenience.

Patient information can be viewed not
only on the unit where the patient is
bedded, but anywhere in the hospital.
For more information on viewing vital
signs on-line, see the next article in this
issue titled, Expect Improvements to
Lastword Chart Tabs.

Myth #5: There are never any
wireless devices available for use
Each CAPOE active unit should have
several PenCentra hand-held devices
available exclusively for physician use.
Two devices reside in both physician
dictation areas. If wireless devices are
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Vital Signs and I/0 - This view
displays only vital signs and
intake/output values*. Values display for
the past seven days at eight-hour
intervals by default.

Expect Improvements to
Lastword Chart Tabs
by Carolyn K. Suess, R.N.
A New Year has arrived and so have
new improvements to the chart tabs in
the Physician Base screen in Lastword.

Intake and Output- This view
displays only intake/output values*.
Values display for the past seven days at
24-hour intervals.

The most significant difference you may
notice is with the Viewer chart tab. The
menu is more descriptive, allowing the
user to better distinguish between the
available views (see Figure 1).

LABS/MICRO- This view displays
only Laboratory and Microbiology
results. Values display for the past sev~n
days and at four-hour intervals by
default.

The views on the chart tab menu are as
follows:
VIEWALL -This view displays
Flowsheet Charted Results* (vital signs,
height/weight, 110), Laboratory results,
and Microbiology results. Values display
for the past seven days and at four-hour
intervals by default.

Definition Screen - This selection
displays the View Definition screen,
offering the ability to select and
customize views.
*This data is only available on patient care units that utilize
electronic entry of vital signs and medication administration.

New Viewer
chart tab menu

Figure 1 -Viewer chart tab displaying new menu selections

3
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The second change impacts the Pt
Care/Chart tab. Typically, only nursing
should use this chart tab to enter vital
signs and patient data. But due to its
name, it sometimes confuses users who
seek patient vital signs. Therefore, the
menu was changed and a link to the
Viewer was added to assist providers in
finding vital signs for their patients (see
Figure 2).

To learn more about the Viewer and
other Lastword features, please take a
moment to review the on-line
documentation for Lastword. Both the
CAPOE and Non-CAPOE Physician
User Guides can be found on the
LVHNN Intranet under the Resources
heading Lastword for Physicians.
If you wish to obtain a paper copy of
either document, or are interested in a
personal training session, please contact
one of the Physician Software Educators
on staff:

To view patient vital signs from the Pt
Care/Chart tab, after selecting a patient
click on the tab to display the menu, then
click on the Vital Signs - PHYSICIAN
selection. The Viewer opens and displays
vital signs and intake/output values for
your patient.

Lynn Corcoran-Stamm - ext.1425
Kimberlee Szep, R.N. - ext. 1431
Carolyn K. Suess, R.N. - ext.1416
Lynn, Kimberlee and Carolyn will be
pleased to assist you.

Pt Care/Chart menu

with link to Viewer
; l

!!

Figure 2 - Pt Care/Chart tab showing new menu selection with link to Viewer
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February 2002
NEWS FROM THE LIBRARY
Computer-Based Training (CBT):
OVID Instruction.
Contact Barb Iobst at 61 0-402-S40S to arrange for instruction
in the use of OVID's MEDLINE and its other databases.

After-Hours Access to L VH-MUHLENBERG Library.
Recently, the LVH-Muhlenberg library door was converted to
a card-access area for the convenience of our patrons. You
can now gain entrance to the Library by running your hospital
I.D. through the card reader outside the door. If your card
does not open the library door, please email Barbara Iobst
with your name and social security number.

Recently Acquired Publications.
Library at 17th and Chew Streets
"Innovations in End-of-Life Care: Practical Strategies and
International Perspectives, " 2000
"Innovations in End-of-Life Care" Vol. 2, 2001

Library at CC & I-78 Campus
"Occupational Medicine: State ofthe Art Reviews."
(Subject: "Health Hazards in the Arts"
December, 2001 -Volume 16, No.4
"Facial Plastic Surgery Clinics ofNorth America."
(Subject: "Vascular Birthmarks o[the Head and Neck"
November, 2001- Volume 9, No.4

Computer Based Training (CBT) programs are available for
LVHHN staff. Topics covered by the CBT programs include:
Power-Point 4.0
Access 2.0
Windows NT 4
Word 97
Excel 97
Access 97
PowerPoint 97
Lotus 1-2-3 Millennium
WordPerfect S
E-mail GUI
PHAMIS LastWord Inquiry Only commands
CBT programs replace the instructor-led classes previously
held at Lehigh Valley Hospital. A proctor will be in the room
with the learner while he/she takes the CBT, but the learner
will control the pace and objectives of the learning.
Computer Based Training takes place in Suite 401 of the
John & Dorothy Morgan Cancer Center (the computer
training room) and in the Muhlenberg Hospital Center
computer training room (off the front lobby). The schedule
of upcoming dates is as follows:
CBT sessions for JDMCC, suite 401 are as follows:
February 12, noon- 4pm
March 26, Sam - noon
April23, Sam- noon
Sessions at MHC, I.S. Training room are as follows:
March 5, noon- 4pm
May 14, noon- 4pm

Library at LVH-Muhlenberg
"Surgical Clinics of North America"
(Subject: "Vascular Trauma: Complex and Challenging
Injuries" Part I)
December, 2001- Volume Sl, No.6

LVH-Muhlenberg and Library 17
"Dental Clinics o[North America. "
(Subject: "Evidence-Based Dentistry"
January, 2002- Volume 46, No.1

Future Educational Activity
Next EPEC conference will be on Thursday, March 14'h
and Friday, March 15th in the School of Nursing?

1

Twelve slots are available for each session.
To register, please contact Suzanne Rice via e-mail or at 610402-2475 with the following:
date of session
second date choice
department
phone number
You will receive an e-mail confirming your choice within two
business days. If you have any questions, please contact Craig
Koller at 610-402-2413 or through e-mail.
Any questions, concerns or comments on articles from CEDS, please contact
Bonnie Schoeneberger 610-402-2584

February
Sun

Man

Tue

Wed

I

Thu

I

Fri

Sat

1
7am GYN GR CC CRI
II am Neurology Conf CC Cr I
12 noon Breast TB JDMCC CR I

3

4
12 noon Colon/Rectal TB
JDMCCCRI

10

11

5
7am Family Practice GR-JDMCC
IA/B
7am Surgical GR CC-Aud
Sam Pediatric GR CC-Aud
12 noon Medical GR CC-Aud

12
7am Surgical GR CC-Aud
Sam Pediatric GR CC-Aud
12 noon Medical GR CC-Aud

17

18
12 noon Colon/Rectal TB
JDMCCCRI

24

25

19
7am Surgical GR CC-Aud
Sam Pediatric GR CC-Aud
12 noon Medical GR CC-Aud

26
7am Surgical GR CC-Aud
Sam Pediatric GR CC-Aud
12 noon Medical GR CC-Aud

6
12 noon MHC TB OR Con
Rm

13
12 noon Pulmonary TB
JDMCCCRI
12 noon MHC TB OR Con
Rm

20
12 noon MHC TB OR Con
Rm

27
12 noon MHC TB OR Con
Rm

7

8

Sam Emergency Medicine
GR Banko Rm 1&2
12 noon Combined TB
JDMCCCRI

?am OBGYN GR CC CRI
II am Neurology Con fCC Crl
12 noon Breast TB JDMCC CR I

I

2
9

14

15

Sam Emergency Medicine
GR 4'h Fl Conf. Rm
12 noon Combined TB
JDMCCCRI

7am OBGYN GR CC CRI
II am Neurology ConfCC Crl
12 noon Breast TB JDMCC CR I

21

22

Sam Emergency Medicine
GR 4'h Fl ConfRm
12 noon G.I.TB JDMCC
CRI

7am OBGYN GR CC CRI
II am Neurology Conf CC Cr I
12 noon Breast TB JDMCC CR I

16
23

28
7:30am Trauma 2002
Conference Holiday Inn
Sam Emergency Medicine
GR 4'h Fl Con. Rm
12 noon Combined TB
JDMCCCRI

2002

"'tJ
D)

ca
CD

~

Page 35
RECOMMENDATIONS TO THE BOARD OF TRUSTEES
FROM THE GENERAL MEDICAL STAFF
FOR REVISIONS TO THE MEDICAL STAFF BYLAWS
FROM MEETING OF DECEMBER 10, 2001

The following proposed revisions, having received the recommendation of the Bylaws Committee, the
Medical Executive Committee, and the General Medical Staff, are being presented for action.

Registered Dieticians Taking Verbal Orders -A recommendation by the Therapeutics Committee to the
Medical Executive Committee requesting that Registered Dieticians be able to take verbal orders from
physicians related to nutritional care and to document those orders in the patient record was approved at
the 9/4/01 Medical Executive Committee. The corresponding proposed changes to the Rules and
Regulations follow:
C. PATIENT CARE #2:
(a)

(b)

Verbal Orders:
(iv)

Verbal orders shall be taken only by -a prefessieaal regis~erea &llfse Registered Nurses and e!isep~ ~at
tlie fellewiag iaah~a1:1als Hl&y ~ie ·~eRial eraers: jqas"~ieaers, Licensed Practical Nurses, Respiratory
Therapy Technicians, Physical Therapy Technicians, Pharmacists, Registered Dieticians. and
Paramedics practicing under PA Code 117.30 (relating to emergency paramedic services) each with
respect to procedures they are authorized to perform.

(v)

In the Emergency Department, verbal orders may only be given to a Registered Nurse.

(i)

.Telephone orders must be signed within twenty-four (24) hours.

(ii)

A member of the Medical Stilff may, but is not required to, sign the order of another member
of the Medical Staff. A resident physician may sign for another resident physician on his or
her same PGY level or below.

(iii)

Telephone orders shall be taken only by -a prefessieaal regis~erea &llfse Registered Nurses and
eliSef:!~ ~kat ~e fellewiag may ~e ~elepkeae eraers: Respiratory Therapy Technicians,
Physical Therapy Technicians, aae Pharmacists, and Registered Dieticians. aae with respect to
procedures they are authorized to perform.

Telephone Orders:

Certified Registered Nurse Practitioners -In November, 2000 the State Board of Medicine and the State
Board of Nursing have promulgated regulations, which permit qualified Pennsylvania CRNPs to prescribe
and dispense drugs. With this change, the attached changes are being proposed to the Rules and
Regulations:
C. PATIENT CARE #3:
3.

Orders shall be written only by physicians, dentists, oral surgeons, podiatrists, certified registered nurse
practitioners. and physician assistants acting within the scope of their respective licenses and authorized according
to Medical Staff Bylaws and these Rules and Regulations. Orders may only be written by a physician extender
under the following circumstances:
(i)

The physician employs a physician extender whom he or she directly supervises and for whom
he or she has responsibility.

(ii)

The physician extender has been approved and credentialed pursuant to these Bylaws and by
the Governing Body for such duties.

Recommendations to the Board of Trustees
From the General Medical Staff
Meeting of December 10, 2001
Page2
(iii)
Except as specifically noted below, no medication orders may be written by any physician extender unless such order is
written in the presence of and immediately countersigned by the supervising physician. Hewever, 'Nftefe a eeRiHeEI paysieiaa assislaRt
aas aeeH speeiHeally ereEieBtialeEI aBEl appreYeEI ay tae GeYeFHiHg SeEly te preseriae FBeEiieatieHS, SI!Sft erEier. FBI!St ae EleeYFBeHteEI WfteH
rel~·eEI aaEI FBYst ae eeYHtersigaeEI ay tae sYper'>'isiag paysieiaa ·ritftiH 72 aeYFs. The following apply to medication orders written by
physician extenders who are specifically credentialed and approved by the Governing Body to prescribe medications:
a.

Certified registered nurse practitioners - Countersignature by the collaborative
physician is not required.

b.

Certified physician assistants -The order must be documented when relayed and
must be countersigned by the supervising physician within 72 hours.

(iv)

Certified physician assistants may write routine diagnostic, diet, and activity orders as directed
and countersigned by the supervising physician.

(v)

All medical student orders shall be countersigned by a licensed physician.

(vi)

Certified registered nurse practitioner orders do not require countersignature by their
collaborative physician.

17.

Members of the Medical Staff, and appropriately credentialed certified registered nurse practitioners and physician
assistants, are responsible for providing a complete medication order. All orders for medications or intravenous
solutions should contain the drug nomenclature, strength, frequency of dosage, and route of administration, where
applicable. With respect to intravenous solutions, the desired flow rate and/or volume should be included. Ordering
medication by package size (e.g. one ampule, a vial, etc.) is considered an incomplete order and will require
clarification by the Pharmacist. Certain combination injectable products do not contain clear quantitative
descriptions and are exempt from this requirement. These include multi-vitamin injections and standard injectable
multi-trace elements.

18.

Drugs shall be administered only upon· the proper order of a practitioner, appropriately credentialed certified
registered nurse practitioner. or appropriately credentialed physician assistants, acting within the scope of his or her
license and authorized according to these Medical Staff Bylaws and Rules and Regulations. Drugs shall be
administered directly by a practitioner qualified according to Medical Staff Bylaws, Rules and Regulations, or by a
certified registered nurse practitioner. er-ey a prefessieaal registered nurse or by a licensed practical nurse with
pharmacy training. Graduate practical nurses, graduate nurses, and students in approved schools of nursing may be
authorized to administer drugs, but only under the supervision of a registered prefessieaal nurse or a physician
under 49 PA Code 21.14 (relating to the administration of drugs).

19.

Narcotics and other dangerous medications (as defined by the Pharmacy & Therapeutics Committee and/or Medical
Executive Committee) that are ordered without time limitation of dosage shall be automatically discontinued after
seventy-two (72) hours. Drugs shall not be discontinued without notifying the physician at least 48 hours before an
order is automatically stopped. If the order expires after 12:00 a.m., it shall be called to the attention of the
physician after 6:00 am. on the same day. Members of the Medical Staff, and appropriately credentialed certified
registered nurse practitioners and physician assistants, shall make every effort to order only those drugs, or the
generic equivalents, listed in the Facility's Formulary. Under special circumstances, drugs not listed in the
Formulary, but necessary for the patient, will be obtained by the pharmacy. Any drugs so ordered, but not yet
approved by the FDA, must be approved by the institution or Review Committee, prior to its administration.

20.

In order to prevent the continuation of antibiotics and steroids in dosages larger or periods of time longer than
indicated, all new or rewritten orders for antibiotics and steroids, shall specify a time limit for administration of the
drug. In the event that no limit is specified, the ordering member of the Medical Staff, or appropriately credentialed
certified registered nurse practitioner or physician assistant, shall be contacted within twenty-four (24) hours to so
specify. Unless otherwise specified, all antibiotic orders shall be instituted as STAT orders.

Chiropractor Clinical Duties - Clinical duties have been approved by the Medical Executive Committee
for Chiropractors which requires the following change to the Rules and Regulations:
C. PATIENT CARE #3:
3.

Orders shall be written only by physicians, dentists, oral surgeons, podiatrists, certified registered nurse
practitioners, chiropractors. and physician assistants acting within the scope of their respective licenses and
authorized according to Medical Staff Bylaws and these Rules and Regulations. Orders may only be written by a
physician extender under the following circumstances:
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Deletion of New Procedure Committee - The recent approval of the Technology Assessment Committee
eliminates the need for the New Procedure Committee as the TAC Committee is a more inclusive
Committee for the acquisition and/or implementation of new technology or advances in existing
technology. Recommendation was made to delete the New Procedure Committee:
fl.

!>levi' PreeeEiHres CeRlHlittee:
(i)

(ii)

(iii)

· Psmese: Te review ~e feasieili~· ef aaEI pelieies fer the i!Bfllemeamtiea ef ae•.v preeeEisres,
teehHi!iHes aaEI treatmeat meEialities ia the Hespitals. A aew preeeEisre is a preeeEiHre, teehHi!iHe er
treatmelilt J:Beeality that is IiSee iH the R9Sflital 91i1 a patielilt, eKSIHeiag researee Stlieies QflQ HeW
EIRigs, tl:!at l:!as Bet eeea Eleae pre~·iessl;y at the applieaele Hespital.
Dsties:
A.

Te meet at least !iliat'terly, er mere eftea whea eallee lifl9H e;y Departmeat ChaiFf!erseas
er the MeEiieal eKeeHtive CeRlHlittee, fer the flliFfl9Se ef re¥iewiag aae reeemmeaEiiag
iastitlitieaal pelie~· fer the implemeamtiea eflilew preeeEiHres, teehlili!iHes aaEI treatmeat
meEialities.

8.

Te repert the results ef the Cei:BBlittee' s iavestigatieas iH the feFJ:B ef a reeeHUBeaeatiea
te the Me&ieal eKeestive Cei:BBlittee iaelaSiHg a ee!Bfllete eeseriptiea ef the preeeEiHre, a
fiaaneial aaalysis, aae reeeHUBeHEieEI ereeeatialiag eriteria fer ~e HeW preeedl:lre.

Cemeesitiea:
ChaiFf!ersea Me&ieal Staff Memeer
Reeer&iag Seereta:Fj
AEimiaistrati•Je SeF¥iees/Assistant te the Presieeat
'Dfreeter, Safe~·
'Dfreeter, Bie Me&ieal eagilleeriag
Fiaaneial SeF¥iees FiBaaeial ,'\Halyst
Risk Maaager
(ti) Me&ieal Staff Memeers

Rules and Regulations - E. Records - #20 - ("Housekeeping detail") - The following is a "housekeeping"
issue to update the Rules and Regulations to conform to current administrative titles:
20.

Free access to all medical records of all patients shall be afforded to members of the Medical Staff in good standing
for bona fide study. Any study must preserve the confidentiality of personal information concerning individual
patients. Certain studies may fall within the category of peer review. As a result, all studies must have prior
approval by:
(a)

an appropriate Audit Committee; or

(b)

Chairperson of the Department; or

(c)

the Seaier Viee PresideRt Chief Medical Officer fer Cliaieal SBF¥iees or Viee PresiEieat ef MeEiieal
Affairs Senior Medical Director.
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Health Network
LABORATORIES

LAB-LINK
Information And Advice About Our Laboratory
January 2, 2002

Effective January 16, 2002, Health Network Laboratories (HNL) will implement a change in
methodology for Troponin I and Creatine Phosphokinase Isoenzyme both of which are
orderable separately and are included in a MI Profile.

SPECIMEN REQUIREMENTS:
•
Troponin I
•
Creatine Phosphokinase Isoenzyme
(Total CK and Mass CK-MB fraction)
•
MI Profile

one green top
(lithium heparin)
)

tube

.

NEW ORDER CODES·
TEST
MI Profile, Initial
MI Profile, #2
MI Profile, #3
Troponin I
Creatine Phospho1inase Isoenzyme

NEW REFERENCE RANGES·.
OLD
Interpretation TROPONIN
of Results
Reference
Range
Consistent with
< 0.10 ng/mL
non-MI condition
Consistent with
MI condition
(Critical Call
Back Value)

> 1.00 ng/mL

OLD TEST CODE
MIIN
MI2
MI3

NEW TEST CODE
MIPIN
MIP2
MIP3

TROPN
CKI

TROPI
CKIMB

NEW
TROPONIN
Reference
Range
<0.08ng/mL

MCKMB
Reference
Range
< 3.38 ng/mL

NEW
MCKMB
Reference
Range
< 2.37 ng/mL

> 0.40ng/mL

> 3.38 ng/mL

> 2.37 ng/mL

OLD

Please post this announcement to ensure compliance onjanuary 16. 2002.
If you have any questions, please contact Dolores Benner at 610-402-8177 or our Customer Care Call
Center at 610-402-8170.
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